Longwalk Biotech

Longwalk Bio is a biotechnology company focused on developing high-throughput, long-read epigenetic mapping technologies to decode the human genome's regulatory landscape. Founded by genomics pioneers Feng Zhang, Bradley Bernstein, and Jason Buenrostro, the company leverages advanced sequencing to identify epigenetic modifications across long DNA segments. This platform aims to uncover novel therapeutic targets and regulatory mechanisms that were previously inaccessible with short-read technologies. By integrating computational biology with precision epigenomics, Longwalk Bio seeks to accelerate the discovery and development of next-generation precision medicines. The company is currently in stealth mode and is backed by leading venture capital firms including ARCH Venture Partners and GV.